Latest Conference Coverage


Carrie Hersh, DO, MSc

Natalizumab Improves Social and Mental Health in Patients with Multiple Sclerosis

April 24th 2021

Researchers compared Neuro-QoL scores between patients treated with natalizumab and ocrelizumab, another high-efficacy treatment for MS.


The Long-Term Efficacy of Inebilizumab in NMOSD: Bruce Cree, MD, PhD, MAS

The Long-Term Efficacy of Inebilizumab in NMOSD: Bruce Cree, MD, PhD, MAS

April 24th 2021

The clinical research director at the UCSF Multiple Sclerosis Center discussed the findings of the long-term open-label assessment of inebilizumab in neuromyelitis optica spectrum disorder.


Fenfluramine Improves Executive Function in Lennox-Gastaut Syndrome

Fenfluramine Improves Executive Function in Lennox-Gastaut Syndrome

April 24th 2021

Improvement was statistically significant for Cognition and the Global Executive Composite score, where approximately twice as many patients achieved clinically meaningful improvement.


Advantages of Fremanezumab Among CGRP Migraine Agents: Stephanie J. Nahas, MD

Advantages of Fremanezumab Among CGRP Migraine Agents: Stephanie J. Nahas, MD

April 23rd 2021

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University detailed the reasons fremanezumab stands out among a crowded migraine treatment landscape.


Nipocalimab Shows Promise as Myasthenia Gravis Treatment: Jeffrey Guptill, MD, MS, MHS

Nipocalimab Shows Promise as Myasthenia Gravis Treatment: Jeffrey Guptill, MD, MS, MHS

April 23rd 2021

The associate professor of neurology and neurologist at Duke University discussed the positive results of nipocalimab, a monoclonal antibody, in patients with myasthenia gravis.


Novel Mobile Toolbox Battery Could Improve Cognitive Impairment Detection

Novel Mobile Toolbox Battery Could Improve Cognitive Impairment Detection

April 22nd 2021

The MTB is built to safely, remotely, and effectively collect data from assessments that measure the executive function, language, memory, and processing speed of adults, and can be captured via smartphone.


Robert J. Fox, MD

IMU-838 Efficacious and Well-Tolerated in Relapsing Multiple Sclerosis

April 22nd 2021

The therapy has fewer off-target effects on kinases and may be better-tolerated than other DHODH inhibitors for patients with relapsing MS.


Aspirin Holds Potential for Stroke Prevention in Cerebral Amyloid Angiopathy

Aspirin Holds Potential for Stroke Prevention in Cerebral Amyloid Angiopathy

April 22nd 2021

The findings add to the body of evidence for use of antiplatelets in patients with cerebral amyloid angiopathy.


Atogepant Continues to Shine in Phase 3 ADVANCE Study: Lawrence Severt, MD, PhD

Atogepant Continues to Shine in Phase 3 ADVANCE Study: Lawrence Severt, MD, PhD

April 22nd 2021

The director at AbbVie discussed a number of abstracts presented at AAN 2021 involving atogepant and its phase 3 ADVANCE study.


Nancy Foldvary-Schaefer, DO, MS

Lower-Sodium Oxybate Has Similar Efficacy, Easily Transitions From Higher-Sodium Oxybate

April 21st 2021

Researchers saw the least amount of adverse events and the least time to stable dose in participants entering the study with SXB treatment.


Jason Poon, MD

Telestroke Accurately Distinguishes Ischemic Stroke From Stroke Mimics

April 21st 2021

Researchers from the University of Utah analyzed the use of their telestroke system with 27 outside “stroke” facilities.


Jason Poon, MD

Applications of Telestroke and Teleneurology: Jason Poon, MD

April 21st 2021

The neurologist at University of Utah discussed his research presented at AAN 2021 on telestroke’s accuracy of differentiating between acute ischemic stroke and mimics.


Inebilizumab Has Enduring Effect as NMOSD Treatment

Inebilizumab Has Enduring Effect as NMOSD Treatment

April 21st 2021

Patients in the randomized controlled trial and the open-label extension treated with inebilizumab experienced similar rates of being attack-free, extending as far as 4 years.


Ublituximab and the Anti-CD20 Class in Multiple Sclerosis: Lawrence Steinman, MD

Ublituximab and the Anti-CD20 Class in Multiple Sclerosis: Lawrence Steinman, MD

April 21st 2021

The professor of neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford Medicine discussed the ULTIMATE trial data presented at the 2021 AAN Annual Meeting.


NeuroVoices: Joseph Sirven, MD, on Expanding Research on Social Determinants of Health in Epilepsy

NeuroVoices: Joseph Sirven, MD, on Expanding Research on Social Determinants of Health in Epilepsy

April 21st 2021

The professor of neurology at Mayo Clinic discussed the need for understanding more about how social determinants of health can impact epilepsy treatment delays.


Clive Ballard, MD

Pimavanserin vs Off-Label Psychotics for Dementia-Related Psychosis: Clive Ballard, MD

April 20th 2021

The dean at the University of Exeter Medical School discussed the questions related to treating dementia-related psychosis and the options available.


Treatment Compliance Higher Among Ofatumumab-Treated Patients Than Teriflunomide

Treatment Compliance Higher Among Ofatumumab-Treated Patients Than Teriflunomide

April 20th 2021

Patient/guardian decision, adverse event, and physician decision were the 3 noted reasons for discontinuation with either ofatumumab or teriflunomide.


Stem Cell Therapy for Spinal Cord Injury on Pace to Soon Enter Human Phase Testing

Stem Cell Therapy for Spinal Cord Injury on Pace to Soon Enter Human Phase Testing

April 20th 2021

In an AAN plenary talk, Mark H. Tuszynski, MD, PhD, detailed the work he and colleagues have done to push stem cell therapy from the lab to the clinic to improve care for spinal cord injury.


Sana Somani, MD, MBBS

African American Women Experience Greatest Disadvantage in Post-Stroke Rehabilitation

April 20th 2021

Researchers analyzed disparities in stroke rehab and found that women and African Americans had the lowest functional performance.


Trends in Movement Disorder Research: Ihtsham ul Haq, MD, FAAN

Trends in Movement Disorder Research: Ihtsham ul Haq, MD, FAAN

April 20th 2021

The chief of Movement Disorders Division at the University of Miami Miller School of Medicine discussed some of the recent focused efforts to uncover more about Parkinson disease and what is on the horizon.


Fremanezumab Demonstrates Efficacy and Safety in Pair of AAN Posters

Fremanezumab Demonstrates Efficacy and Safety in Pair of AAN Posters

April 20th 2021

Patients with a previous history of cardiovascular risks experienced similarly low number of cardiovascular events with treatment of fremanezumab compared with placebo.


Validated MANAGE-PD Tool May Identify Parkinson Disease Treatment Gaps

Validated MANAGE-PD Tool May Identify Parkinson Disease Treatment Gaps

April 19th 2021

In total, 50% of patients eligible for device-aided therapies did not report having any discussion with providers about future device-aided therapies.


Natalia Rost, MD, MPH, FAAN, FAHA

Treatment Disparities, Neurologic Complications Clarified by COVID-19 Neurological Research

April 19th 2021

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.


Sana Somani, MD, MBBS

Mitigating Disparities in Stroke Rehabilitation Care: Sana Somani, MD, MBBS

April 19th 2021

The vascular neurology fellow at the University of Maryland Medical Center discussed strategies to improve stroke care efficiency in women and African Americans.


Deep Brain Stimulation Leads Advances in Neuromodulation for Movement Disorders

Deep Brain Stimulation Leads Advances in Neuromodulation for Movement Disorders

April 19th 2021

An AAN session included presentations of research on the latest advancements and knowledge in neuromodulation for patients with these disorders.


Efficacy and Safety of Fremanezumab Further Displayed: Stephanie J. Nahas, MD

Efficacy and Safety of Fremanezumab Further Displayed: Stephanie J. Nahas, MD

April 19th 2021

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed 2 research projects she led presented at AAN 2021 on the efficacy and safety of fremanezumab.


Marian LaMonte, MD, MSN, FAAN

Implementing Patient-Specific Stroke Discharge Instructions: Marian LaMonte, MD, MSN, FAAN

April 18th 2021

The chief of neurology at Ascension Saint Agnes discussed how providing an overview of patient-specific risk factors and mitigation can improve poststroke care.


Aducanumab EMBARK Trial Seeks to Characterize Treatment Durability, Effects of Interruption

Aducanumab EMBARK Trial Seeks to Characterize Treatment Durability, Effects of Interruption

April 18th 2021

Aducanumab currently sits before the FDA for review for the treatment of Alzheimer disease, with a PDUFA date set for June 7, 2021.

© 2025 MJH Life Sciences

All rights reserved.